Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting FY26 consolidated net profit of ₹5,098 million.
Recommended a final dividend of ₹4 per equity share (40% on face value of ₹10) for FY26, subject to shareholder approval at the AGM.
Approved acquisition of 100% stake in Shahbazkers Diagnostic Centre for up to ₹20 crores to strengthen Mumbai presence.
Re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as Independent Director for five-year terms.